• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter

    7/16/24 8:16:01 AM ET
    $AVAH
    $FULC
    $RVMD
    Medical/Nursing Services
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVAH alert in real time by email

    As of July 16, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

    The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro.

    Here's the latest list of major overbought players in this sector.

    Aveanna Healthcare Holdings Inc (NASDAQ:AVAH)

    • On May 9, Aveanna Healthcare posted a narrower-than-expected quarterly loss. Jeff Shaner, Chief Executive Officer, commented, “Our first quarter results reflect the continued positive momentum at Aveanna, highlighted by revenue and Adjusted EBITDA growth of 5.2% and 22.5% respectively, when compared to the prior year period.” The company's stock gained around 38% over the past five days and has a 52-week high of $3.66.
    • RSI Value: 76.61                              
    • AVAH Price Action: Shares of Aveanna Healthcare gained 10.3% to close at $3.52 on Monday.

    Revolution Medicines Inc (NASDAQ:RVMD)

    • On July 12, Barclays analyst Peter Lawson initiated coverage on Revolution Medicines with an Overweight rating and announced a price target of $52. The company's stock gained around 24% over the past month and has a 52-week high of $48.61.
    • RSI Value: 75.60
    • RVMD Price Action: Shares of Revolution Medicines gained 1.9% to close at $46.00 on Monday.

    Fulcrum Therapeutics Inc (NASDAQ:FULC)

    • On July 10, Cantor Fitzgerald analyst Kristen Kluska reiterated Fulcrum Therapeutics with an Overweight and maintained a $23 price target. The company's stock gained around 40% over the past five days and has a 52-week high of $13.70.
    • RSI Value: 70.72
    • FULC Price Action: Shares of Fulcrum Therapeutics gained 5.5% to close at $8.45 on Monday.

    Read Next:

    • Bank Of America, Morgan Stanley And Other 3 Stocks To Watch Heading Into Tuesday
    Get the next $AVAH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVAH
    $FULC
    $RVMD

    CompanyDatePrice TargetRatingAnalyst
    Revolution Medicines Inc.
    $RVMD
    3/16/2026Buy
    Jefferies
    Revolution Medicines Inc.
    $RVMD
    2/27/2026$145.00Buy
    UBS
    Fulcrum Therapeutics Inc.
    $FULC
    1/12/2026$20.00Overweight
    Analyst
    Aveanna Healthcare Holdings Inc.
    $AVAH
    12/8/2025Outperform
    William Blair
    Fulcrum Therapeutics Inc.
    $FULC
    11/24/2025Buy
    Truist
    Revolution Medicines Inc.
    $RVMD
    11/18/2025$75.00Outperform
    Wolfe Research
    Aveanna Healthcare Holdings Inc.
    $AVAH
    11/13/2025$11.00Outperform
    BMO Capital Markets
    Revolution Medicines Inc.
    $RVMD
    11/3/2025$77.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $AVAH
    $FULC
    $RVMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Schroeder Thilo bought $59,999,962 worth of shares (1,304,347 units at $46.00) (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    12/9/24 4:15:16 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sapir Alex bought $492,028 worth of shares (43,360 units at $11.35) (SEC Form 4)

    4 - Fulcrum Therapeutics, Inc. (0001680581) (Issuer)

    3/5/24 4:15:17 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVAH
    $FULC
    $RVMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease

    CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- MedicAlert Foundation, the leading nonprofit providing medical IDs and emergency medical information services, Sickle Cell Disease Association of America, Inc., (SCDAA), the national voice for people affected by sickle cell disease and their caregivers, and Fulcrum Therapeutics Inc. (Fulcrum) (NASDAQ:FULC), a leader in advancing therapies for underserved patient populations, today announced a new partnership designed to help streamline and expedite emergency department (ED) care for people living with sickle cell disease (SCD) through rapid access to patient-specific care plans. Individuals living with SCD, an inherited blood disorder,

    3/19/26 8:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aveanna Healthcare Holdings Announces Fourth Quarter and Full Year 2025 Financial Results

    Fourth Quarter Revenue was $662.5 million, a 27.4% increase over the prior year periodFourth Quarter Net income was $178.8 million compared to $29.2 million for the prior year periodAdjusted EBITDA for Q4 2025 was $85.0 million, a 54.0% increase over the prior year periodMaintained Full Year 2026 Revenue guidance of between $2.54 and $2.56 billion Maintained Full Year 2026 Adjusted EBITDA guidance of between $318 and $322 million Announced agreement to acquire Family First Homecare subsequent to the Fourth Quarter ATLANTA, March 19, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH), a leading, diversified home care platform focused on providing care to medically comp

    3/19/26 7:00:00 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Aveanna Healthcare Holdings Announces Agreement to Acquire Family First Homecare

    ATLANTA, March 12, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced that it has entered into an agreement to acquire Family First Holding, LLC ("Family First Homecare"). Family First Homecare is a scaled, multi-state provider of pediatric home care that primarily provides skilled Private Duty Nursing services with 27 locations in seven states including Florida, Illinois, Iowa, Pennsylvania, South Dakota, Texas, and North Carolina, where it is currently launching operations. The acquisition of Family First Homecare expands Aveanna'

    3/12/26 7:30:00 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    $AVAH
    $FULC
    $RVMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies resumed coverage on Revolution Medicines

    Jefferies resumed coverage of Revolution Medicines with a rating of Buy

    3/16/26 9:35:47 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Revolution Medicines with a new price target

    UBS resumed coverage of Revolution Medicines with a rating of Buy and set a new price target of $145.00

    2/27/26 8:31:41 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Analyst initiated coverage on Fulcrum Therapeutics with a new price target

    Analyst initiated coverage of Fulcrum Therapeutics with a rating of Overweight and set a new price target of $20.00

    1/12/26 8:13:43 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVAH
    $FULC
    $RVMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Weil Samuel Altman

    3 - Aveanna Healthcare Holdings, Inc. (0001832332) (Issuer)

    3/18/26 5:30:07 PM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Director Anderson Elizabeth M received a gift of 15,000 shares and gifted 15,000 shares, decreasing direct ownership by 65% to 8,215 units (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    3/6/26 6:20:31 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Officer Wang Xiaolin was granted 15,100 shares, increasing direct ownership by 15% to 118,073 units (SEC Form 4)

    4 - Revolution Medicines, Inc. (0001628171) (Issuer)

    3/3/26 9:11:14 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVAH
    $FULC
    $RVMD
    SEC Filings

    View All

    Aveanna Healthcare Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Aveanna Healthcare Holdings, Inc. (0001832332) (Filer)

    3/19/26 7:00:10 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    SEC Form 144 filed by Revolution Medicines Inc.

    144 - Revolution Medicines, Inc. (0001628171) (Subject)

    3/13/26 7:38:27 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Revolution Medicines Inc.

    144 - Revolution Medicines, Inc. (0001628171) (Subject)

    3/13/26 7:36:20 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVAH
    $FULC
    $RVMD
    Leadership Updates

    Live Leadership Updates

    View All

    Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

    REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the appointment of Alan Sandler, M.D. into the newly created role of chief development officer, as well as the appointment of regional general managers in the U.S. and Europe. "I am delighted to welcome Alan as our chief development officer as we pursue our bold vision to develop new global standards of care for patients with RAS-addicted cancers," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. "As a physician-

    9/29/25 9:00:15 AM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Aveanna Healthcare Holdings Announces Appointment of New Director

    ATLANTA, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH), a leading, diversified home care platform focused on providing care to medically complex, high-cost patient populations, today announced the appointment of Brent Layton to serve as a Class III director of the Board of Directors of Aveanna Healthcare Holdings Inc., and additionally as a member of the Audit Committee of the Board, effective November 1, 2024. "I am delighted to announce the appointment of Brent Layton to our Aveanna Board of Directors. Brent brings a wealth of healthcare knowledge from over 20 years of leadership at Centene Corporation. Brent's experience working with state and feder

    11/4/24 7:30:02 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Fulcrum Therapeutics Strengthens Leadership Team with the Appointments of Isabel Kalofonos as Chief Commercial Officer and Heather Faulds as Chief Regulatory Affairs & Quality Assurance Officer

    CAMBRIDGE, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced the appointment of Isabel Kalofonos as chief commercial officer and Heather Faulds as chief regulatory affairs & quality assurance officer. Together, Ms. Kalofonos and Ms. Faulds will be instrumental in advancing losmapimod towards a New Drug Application (NDA) submission and preparing for commercial launch. "I am excited to welcome Isabel to our leadership team as we continue to advance towards the potential approval a

    8/19/24 7:00:00 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVAH
    $FULC
    $RVMD
    Financials

    Live finance-specific insights

    View All

    Aveanna Healthcare Holdings Announces Fourth Quarter and Full Year 2025 Financial Results

    Fourth Quarter Revenue was $662.5 million, a 27.4% increase over the prior year periodFourth Quarter Net income was $178.8 million compared to $29.2 million for the prior year periodAdjusted EBITDA for Q4 2025 was $85.0 million, a 54.0% increase over the prior year periodMaintained Full Year 2026 Revenue guidance of between $2.54 and $2.56 billion Maintained Full Year 2026 Adjusted EBITDA guidance of between $318 and $322 million Announced agreement to acquire Family First Homecare subsequent to the Fourth Quarter ATLANTA, March 19, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. (NASDAQ:AVAH), a leading, diversified home care platform focused on providing care to medically comp

    3/19/26 7:00:00 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Aveanna Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call

    ATLANTA, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare Holdings Inc. ("Aveanna") (NASDAQ:AVAH) today announced that the company will release its fourth quarter and full year results before the market open on Thursday, March 19, 2026, to be followed by a conference call at 10:00 a.m. (Eastern Time) on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0789 or for international callers, 1-201-689-8562. A replay will be available three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 13757396. The replay will be available until March

    2/26/26 6:30:00 AM ET
    $AVAH
    Medical/Nursing Services
    Health Care

    Revolution Medicines Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

    On track for readout of RASolute 302, a Phase 3 trial of daraxonrasib in second line metastatic PDAC, in first half of 2026Continues to advance broad late-stage pipeline, with five ongoing Phase 3 trials and three additional Phase 3 trials planned to initiate in 2026Expects to substantially complete enrollment in RASolve 301, a Phase 3 trial of daraxonrasib in previously treated NSCLC, this yearInitiated RASolute 305, the first Phase 3 trial for zoldonrasib, in first line metastatic PDAC harboring a RAS G12D mutationRevolution Medicines to hold webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (NASDAQ:RVMD), a late-s

    2/25/26 4:02:00 PM ET
    $RVMD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $AVAH
    $FULC
    $RVMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/14/24 4:25:46 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/14/24 6:15:07 AM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Fulcrum Therapeutics Inc.

    SC 13G/A - Fulcrum Therapeutics, Inc. (0001680581) (Subject)

    11/12/24 3:51:00 PM ET
    $FULC
    Biotechnology: Pharmaceutical Preparations
    Health Care